Citations

Clear

3030 citation(s) found for "Susan, M".

Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma
Maurer, Matthew J. , Link, Brian K. , Ansell, Stephen M. , Micallef, Ivana N. , Kelly, Jennifer L., Macon, William R. , Nowakowski, Grzegorz S. , Inwards, David J. , Johnston, Patrick B. , Allmer, Cristine, Weiner, George J. , Cerhan, James R. , Drake, Matthew T. , Habermann, Thomas M. , Singh, Ravinder J. , Slager, Susan L. , Witzig, Thomas E. , Maurer, Matthew , Cerhan, James R , Link, Brian K , Weiner, George

Mayo Clinic

Journal of Clinical Oncology | August 17, 2010 | Volume: 28 | Issue: 27 | Pages: 4191-4198

10.1200/jco.2010.28.6674 | PMID 20713849 Get It

Purpose Vitamin D insufficiency is common in the United States, with low levels linked in some studies to higher cancer incidence, including non-Hodgkin's lymphoma (NHL). Recent data also suggest that vitamin D insufficiency is related to inferior prognosis in some cancers, although there are no data for NHL. Patients and Methods We tested the hypothesis that circulating 25-hydroxyvitamin D [25(OH)D] levels are predictive of event-free survival (EFS) and overall survival (OS) in a prospective cohort of 983 newly diagnosed patients with NHL. 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels were measured by liquid chromatography-tandem mass spectrometry. Results Mean age at diagnosis was 62 years (range, 19 to 94 years); 44% of patients had insufficient 25(OH)D levels (< 25 ng/mL) within 120 days of diagnosis. Median follow-up was 34.8 months; 404 events and 193 deaths (168 from lymphoma) occurred. After adjusting for known prognostic factors and treatment, 25(OH)D insufficient patients with diffuse large B-cell lymphoma (DLBCL) had inferior EFS (hazard ratio [HR], 1.41; 95% CI, 0.98 to 2.04) and OS (HR, 1.99; 95% CI, 1.27 to 3.13); 25(OH)D insufficient patients with T-cell lymphoma also had inferior EFS (HR, 1.94; 95% CI, 1.04 to 3.61) and OS (HR, 2.38; 95% CI, 1.04 to 5.41). There were no associations with EFS for the other NHL subtypes. Among patients with DLBCL and T-cell lymphoma, higher 1,25(OH)2D levels were associated with better EFS and OS, suggesting that any putative tumor 1-α-hydroxylase activity did not explain the 25(OH)D associations. Conclusion 25(OH)D insufficiency was associated with inferior EFS and OS in DLBCL and T-cell lymphoma. Whether normalizing vitamin D levels in these patients improves outcomes will require testing in future trials.
Dyssynchrony Indices To Predict Response to Cardiac Resynchronization Therapy
Miyazaki, Chinami , Redfield, Margaret M. , Powell, Brian D. , Lin, Grace, Herges, Regina M., Hodge, David O. , Olson, Lyle J. , Hayes, David L. , Espinosa, Raúl E. , Rea, Robert F., Nelson, Susan M., Miller, Fletcher A., Oh, Jae K. , Bruce, Charles J.

Mayo Clinic

Circulation: Heart Failure | July 21, 2010 | Volume: 3 | Issue: 5 | Pages: 565-573

10.1161/circheartfailure.108.848085 | PMID 20647479 Get It

Background— Whether mechanical dyssynchrony indices predict reverse remodeling (RR) or clinical response to cardiac resynchronization therapy (CRT) remains controversial. This prospective study evaluated whether echocardiographic dyssynchrony indices predict RR or clinical response after CRT. Methods and Results— Of 184 patients with heart failure with anticipated CRT who were prospectively enrolled, 131 with wide QRS and left ventricular ejection fraction <35% had 6-month follow-up after CRT implantation. Fourteen dyssynchrony indices (feasibility) by M-mode (94%), tissue velocity (96%), tissue Doppler strain (92%), 2D speckle strain (65% to 86%), 3D echocardiography (79%), and timing intervals (98%) were evaluated. RR (end-systolic volume reduction ≥15%) occurred in 55% and more frequently in patients without (71%) than in patients with (42%) ischemic cardiomyopathy ( P =0.002). Overall, only M-mode, tissue Doppler strain, and total isovolumic time had a receiver operating characteristic area under the curve (AUC) greater than the line of no information, but none of these were strongly predictive of RR (AUC, 0.63 to 0.71). In nonischemic cardiomyopathy, no dyssynchrony index predicted RR. In ischemic cardiomyopathy, M-mode (AUC, 0.67), tissue Doppler strain (AUC, 0.79), and isovolumic time (AUC, 0.76) -derived indices predicted RR ( P <0.05 for all), although the incremental value was modest. No indices predicted clinical response assessed by Minnesota Living with Heart Failure Questionnaire, 6-minute walk distance, and peak oxygen consumption. Conclusions— These findings are consistent with the Predictors of Response to CRT study and do not support use of these dyssynchrony indices to guide use of CRT.
O3‐03‐08: Biomarker predictors of cognitive decline in healthy older participants in the Alzheimer's Disease Neuroimaging Initiative
Landau, Susan , Reiman, Eric M. , Foster, Norman L. , Aisen, Paul , Trojanowski, John Q. , Shaw, Leslie M. , Petersen, Ronald C. , Weiner, Michael W. , Jagust, William J. , Harvey, Danielle , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2010.05.411 Get It

Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report
Fouladi, Maryam , Stewart, Clinton F. , Gilbertson, Richard J. , Sun, Junfeng , Ames, Matthew M. , Speights, Roseanne, Ingle, Ashish M., Blaney, Susan M. , Adamson, Peter C. , Park, Julie R. , Schaiquevich, Paula S. , Reid, Joel M. , Zwiebel, James A.

Mayo Clinic

Journal of Clinical Oncology | July 7, 2010 | Volume: 28 | Issue: 22 | Pages: 3623-3629

10.1200/jco.2009.25.9119 | PMID 20606092 Get It

Purpose The purpose of this study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of vorinostat administered as a single agent and in combination 13-cis retinoic acid (13cRA) in children with refractory solid tumors; to evaluate the tolerability of the solid tumor MTD in children with refractory leukemias; and to characterize the pharmacokinetics of a vorinostat suspension in children. Patients and Methods Vorinostat was administered orally daily starting at 180 mg/m2/d with escalations planned in 30% increments. Pharmacokinetic studies were performed with the initial dose. Acetyl-histone (H3) accumulation was assessed by Western blotting of peripheral blood mononuclear cells (PBMC). Results Sixty-four patients were enrolled on this multipart trial. In patients with solid tumors, the MTD was 230 mg/m2/d with dose-limiting neutropenia, thrombocytopenia, and hypokalemia at 300 mg/m2/d. DLTs observed with the combination of 13cRA and vorinostat included thrombocytopenia, neutropenia, anorexia, and hypertriglyceridemia, resulting in a MTD of vorinostat 180 mg/m2/d 4 times per week and 13cRA 80 mg/m2/dose twice per day, days 1 through 14 every 28 days. Wide interpatient variability was noted in vorinostat disposition, with area under the concentration-time curves at 230 mg/m2/d for the capsule (range, 1,415 to 9,291 ng/mL × hr) and oral suspension (range, 1,186 to 4,780 ng/mL × hr). Significant accumulation of acetylated H3 histone in PBMC was observed after administration of vorinostat, particularly at higher doses. One patient with neuroblastoma experienced a complete response to the combination. Conclusion In children with recurrent solid tumors, vorinostat is well-tolerated at 230 mg/m2/d, with a modest dose reduction being required when combining vorinostat with 13cRA. Drug disposition is similar to that observed in adults.
Platelet-derived growth factor (PDGF)–PDGF receptor interaction activates bone marrow–derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch
Knox, Traci R., Tschumper, Renee C. , Schwager, Susan M., Boysen, Justin C. , Jelinek, Diane F., Ding, Wei , Wu, Wenting , Kay, Neil E.

Mayo Clinic

Blood | July 6, 2010 | Volume: 116 | Issue: 16 | Pages: 2984-2993

10.1182/blood-2010-02-269894 | PMID 20606160 Get It

Abstract Malignant cells are capable of influencing the microenvironment in a manner that facilitates tumor cell survival. Bidirectional crosstalk between chronic lymphocytic leukemic (CLL) cells and marrow-derived mesenchymal stromal cells (MSCs) activates both cell types. In this study, we observed that the conditioned medium (CM) obtained from CLL cells was able to induce Akt activation in MSC. Subsequent studies investigated the mechanism of MSC activation mediated by CLL-CM. Platelet-derived growth factor receptors (PDGFRs) were selectively activated in MSCs by CLL-CM and found to be critical receptors for CLL-CM–driven MSC proliferation and MSC Akt activation. The known ligands of PDGFR, platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), were detected in CLL-CM, but PDGF was the predominant ligand involved in the CM-mediated PDGFR activation. Both PDGF and VEGF were found to be elevated in the plasma of CLL patients with a positive association for high-risk factors and more advanced stage. Finally, we demonstrated that PDGF induced MSC VEGF production through a phosphatidylinositol 3-kinase (PI3K)–dependent mechanism. These results show that PDGF-PDGFR signaling influences at least the MSC in the microenvironment of CLL and may play a role in the induction of an angiogenic switch known to be permissive for disease progression.
LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis
Gutierrez, Albert, Tschumper, Renee C. , Wu, Xiaosheng , Eckel‐Passow, Jeanette E. , Huddleston, P.M. , Jelinek, Diane F., Shanafelt, Tait D. , Slager, Susan L. , Kay, Neil E. , Huddleston, Paul M

Mayo Clinic

Blood | July 2, 2010 | Volume: 116 | Issue: 16 | Pages: 2975-2983

10.1182/blood-2010-02-269878 | PMID 20595513 Get It

Abstract The canonical Wnt signaling pathway is pathogenic in a variety of cancers. We previously identified aberrant expression of the Wnt pathway transcription factor and target gene lymphoid enhancer binding factor-1 (LEF1) in chronic lymphocytic leukemia (CLL). This suggested that the Wnt signaling pathway has a role in the biology of CLL. In this study, we performed a Wnt pathway analysis using gene expression profiling and identified aberrant regulation of Wnt pathway target genes, ligands, and signaling members in CLL cells. Furthermore, we identified aberrant protein expression of LEF-1 specifically in CLL but not in normal mature B-cell subsets or after B-cell activation. Using the T cell–specific transcription factor/LEF (TCF/LEF) dual luciferase reporter assay, we demonstrated constitutive Wnt pathway activation in CLL, although the pathway was inactive in normal peripheral B cells. Importantly, LEF-1 knockdown decreased CLL B-cell survival. We also identified LEF-1 expression in CD19+/CD5+ cells obtained from patients with monoclonal B-cell lymphocytosis, suggesting a role for LEF-1 early in CLL leukemogenesis. This study has identified the constitutive activation and prosurvival function of LEF-1 and the Wnt pathway in CLL and uncovered a possible role for these factors in the preleukemic state of monoclonal B-cell lymphocytosis.
Comparing predictors of conversion and decline in mild cognitive impairment
Landau, Susan , Harvey, Danielle , Madison, Catherine, Reiman, Eric M. , Foster, Norman L. , Aisen, Paul , Petersen, Ronald C. , Shaw, Leslie M. , Trojanowski, John Q. , Weiner, Michael W. , Jagust, William J. , Jack, Clifford R. , Harvey, Danielle J

Mayo Clinic

Neurology | June 30, 2010 | Volume: 75 | Issue: 3 | Pages: 230-238

10.1212/wnl.0b013e3181e8e8b8 | PMID 20592257 Get It

Hashimoto Thyroiditis: Part 2, Sonographic Analysis of Benign and Malignant Nodules in Patients With Diffuse Hashimoto Thyroiditis
Anderson, Lauren , Middleton, William D. , Teefey, Sharlene A. , Reading, Carl C., Langer, Jill E. , Desser, Terry S. , Szabunio, Margaret M. , Mandel, Susan J., Hildebolt, Charles F. , Cronan, John J.

Mayo Clinic

American Journal of Roentgenology | June 21, 2010 | Volume: 195 | Issue: 1 | Pages: 216-222

10.2214/ajr.09.3680 | PMID 20566819 Get It

Hashimoto Thyroiditis: Part 1, Sonographic Analysis of the Nodular Form of Hashimoto Thyroiditis
Anderson, Lauren , Middleton, William D. , Teefey, Sharlene A. , Reading, Carl C., Langer, Jill E. , Desser, Terry S. , Szabunio, Margaret M. , Hildebolt, Charles F. , Mandel, Susan J., Cronan, John J.

Mayo Clinic

American Journal of Roentgenology | June 21, 2010 | Volume: 195 | Issue: 1 | Pages: 208-215

10.2214/ajr.09.2459 | PMID 20566818 Get It

Confirmation of Linkage to and Localization of Familial Colon Cancer Risk Haplotype on Chromosome 9q22
Gray‐McGuire, Courtney, Guda, Kishore , Adrianto, Indra , Lin, Chee Paul , Natale, Leanna, Potter, John D. , Lindor, Noralane M. , Goode, Ellen L. , Jenkins, Robert B. , Jenkins, Mark A. , Young, Joanne , Buchanan, Daniel D. , Gallinger, Steve, Lewis, Susan, Elston, Robert C. , Markowitz, Sanford D. , Wiesner, Georgia L. , Newcomb, Polly A. , Poole, Elizabeth M. , Ulrich, Cornelia M. , Fridley, Brooke L. , Marchand, Loı̈c Le , Casey, Graham , Haile, Robert W. , Hopper, John L. , Adams, Mark , Lewis, Susan, Willis, Joseph , Buchanan, Daniel D , Jenkins, Mark A , Potter, John D

Mayo Clinic

Cancer Research | June 15, 2010 | Volume: 70 | Issue: 13 | Pages: 5409-5418

10.1158/0008-5472.can-10-0188 | PMID 20551049 Get It

Abstract Genetic risk factors are important contributors to the development of colorectal cancer. Following the definition of a linkage signal at 9q22-31, we fine mapped this region in an independent collection of colon cancer families. We used a custom array of single-nucleotide polymorphisms (SNP) densely spaced across the candidate region, performing both single-SNP and moving-window association analyses to identify a colon neoplasia risk haplotype. Through this approach, we isolated the association effect to a five-SNP haplotype centered at 98.15 Mb on chromosome 9q. This haplotype is in strong linkage disequilibrium with the haplotype block containing HABP4 and may be a surrogate for the effect of this CD30 Ki-1 antigen. It is also in close proximity to GALNT12, also recently shown to be altered in colon tumors. We used a predictive modeling algorithm to show the contribution of this risk haplotype and surrounding candidate genes in distinguishing between colon cancer cases and healthy controls. The ability to replicate this finding, the strength of the haplotype association (odds ratio, 3.68), and the accuracy of our prediction model (∼60%) all strongly support the presence of a locus for familial colon cancer on chromosome 9q. Cancer Res; 70(13); 5409–18. ©2010 AACR.